Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Abstract Text:

Evan Wood,Thomas Kerr,Robert S Hogg,Anita Palepu,Ruth Zhang,Steffanie A Strathdee,Julio S G Montaner,

Improving access to antiretroviral therapy among injection drug users remains an urgent public health concern. We examined the time to antiretroviral therapy (ART) use among antiretroviral naive HIV-infected injection drug users who were unaware of their HIV status to examine the impact of receipt of HIV test results on uptake of ART. Time to ART use was examined using Kaplan - Meier methods, and factors associated with the time to ART were evaluated using Cox proportional hazards regression. Between May 1996 and May 2003, 312 HIV-infected individuals were enrolled into the Barriers to Antiretroviral Therapy (BART) cohort, among whom 105 (33.7%) reported not knowing their HIV status at baseline. At 24 months post-baseline, those participants who returned for test results within 8 months initiated ART at a significantly elevated rate [adjusted relative hazard = 1.87 (95% CI: 1.05 - 3.33)]. These findings demonstrate the potential to improve uptake of ART among injection drug users through targeted HIV testing and counselling initiatives that encourage the receipt of HIV test results, and suggest that strategies to improve awareness of HIV infection may improve access to antiretroviral therapy.

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Publishing Authors By Initials

E Wood,T Kerr,RS Hogg,A Palepu,R Zhang,SA Strathdee,JS Montaner,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Drug and alcohol review

VOLUME: 25

Page Numbers: 451-4

Journal Abbreviation:

ISSN: 0959-5236

DAY: 3

MONTH: Sep

YEAR: 2006

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9015440

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.

AFFILIATION: British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Canada. ewood@cfenet.ubc.ca

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drug Alcohol Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users Related Publications

• A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
• A review of barriers and facilitators of HIV treatment among injection drug users.
• Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
• Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
• Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator related hemorrhagic transformation.
• Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
• Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.
• Ethical and scientific issues surrounding solid organ transplantation in HIV-positive patients: Absence of evidence is not evidence of absence.
• Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage.
• Genetics of stroke: a review of recent advances.
• Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
• Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
• Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption
• Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
• MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.
• Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.
• Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases.
• NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells.
• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
• Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
• Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
• Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?
• Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
• The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
• The use of highly active retroviral therapy to reduce HIV incidence at the population level.
• Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
• Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
• [Biological markers in spontaneous intracerebral hemorrhage]
• [Commentary] ANTIRETROVIRAL THERAPY: A KEY PART OF THE PUBLIC HEALTH RESPONSE TO INJECTION DRUG USE.
• [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]